Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Mallika Dhawan
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Mallika Dhawan
Dr. Dhawan is an assistant professor in Medical Oncology and specializes in the prevention and treatment of hereditary cancer syndromes in the Center for BRCA Research as well as the development of Phase 1 clinical trials for patient with advanced cancers through the Experimental Therapeutics program. She joined UCSF for fellowship in 2014 and remains on as a faculty member.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme Corp.
- Links
- Merck Oncology Clinical Trial Information
- ID
- NCT03742895
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated